lenalidomide has been researched along with pomalidomide in 195 studies
| Studies (lenalidomide) | Trials (lenalidomide) | Recent Studies (post-2010) (lenalidomide) | Studies (pomalidomide) | Trials (pomalidomide) | Recent Studies (post-2010) (pomalidomide) |
|---|---|---|---|---|---|
| 3,532 | 725 | 2,850 | 623 | 121 | 552 |
| Protein | Taxonomy | lenalidomide (IC50) | pomalidomide (IC50) |
|---|---|---|---|
| DNA damage-binding protein 1 | Homo sapiens (human) | 2.1 | |
| Protein cereblon | Homo sapiens (human) | 1.85 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.51) | 18.2507 |
| 2000's | 25 (12.82) | 29.6817 |
| 2010's | 105 (53.85) | 24.3611 |
| 2020's | 64 (32.82) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, R; Chen, Y; Corral, LG; Huang, SY; Kaplan, G; Muller, GW; Patterson, RT; Stirling, DI; Wong, LM | 1 |
| Fujimoto, H; Hashimoto, Y; Miyachi, H; Miyajima, A; Noguchi, T; Sano, H | 1 |
| Abbasian, M; Carmel, G; Cathers, B; Chen, R; Chopra, R; Daniel, TO; Evans, JF; Gaidarova, S; Gandhi, AK; Handa, H; Ito, T; Jackson, P; Kang, J; Karasawa, S; Lopez-Girona, A; Mahmoudi, A; Mendy, D; Miller, K; Rychak, E; Schafer, PH | 1 |
| Babusis, D; Capone, L; Chen, R; Corral, L; Kang, J; Man, HW; Moghaddam, MF; Muller, GW; Parton, A; Ruchelman, AL; Schafer, PH; Shirley, MA; Tang, Y; Zhang, W | 1 |
| Baculi, F; Carmel, G; Condroski, K; Correa, M; Crea, T; Hansen, JD; Hickman, M; LeBrun, L; Liu, W; Lu, CC; Lu, G; Mahmoudi, A; Man, HW; Muller, G; Ruchelman, A; Vocanson, F; Zhang, W | 1 |
| Baculi, F; Carmel, G; Carmichael, J; Cathers, BE; Chamberlain, PP; Daniel, TO; Hickman, M; Khambatta, G; LeBrun, L; Lu, CC; Lu, G; Man, HW; Matyskiela, ME; Muller, G; Pagarigan, B; Riley, M; Satoh, Y; Schafer, P; Zhang, W | 1 |
| Bahlis, NJ; Derksen, DJ; Gorobets, E; MacCallum, JL; Maity, R; Muniyat, MI; Neri, P; Papatzimas, JW | 1 |
| Bär, K; Giannis, A; Hartmann, MD; Heim, C; Hernandez Alvarez, B; Mousavizadeh, F; Pliatsika, D | 1 |
| Alexander, M; Baculi, F; Carmichael, J; Cathers, B; Correa, M; Daniel, T; Ebinger, K; Grant, V; Hamann, LG; Hansen, JD; Harris, R; Havens, CG; Huang, D; Kercher, T; Khambatta, G; LeBrun, LA; Leftheris, K; Leisten, J; Lopez-Girona, A; Mendy, D; Moghaddam, M; Nagy, MA; Narla, RK; Piccotti, J; Plantevin, V; Tang, Y; Vessey, R; Whitefield, B | 1 |
| Cao, F; Chen, D; de Weerd, S; Dekker, FJ; van der Wouden, PE; Zwinderman, MRH | 1 |
| Hogan, L; Kim, MJ; Lassalle-Claux, G; Luiker, K; Murugesan, A; Reiman, T; Selka, A; Touaibia, M; Vaillancourt, E | 1 |
| Hartmann, MD; Heim, C; Hernandez Alvarez, B; Maiwald, S | 1 |
| Andrewartha, N; Buyan, A; Corry, B; Nutt, MJ; Stewart, SG; Yee, YS; Yeoh, GCT | 1 |
| Chen, J; Ding, X; Elvassore, N; Jiang, B; Kong, Y; Liu, H; Liu, L; Mi, Q; Qiu, X; Ren, C; Shao, Y; Yang, X; Yin, Q; Zhao, Q | 1 |
| Che, J; Jones, LH; Kong, NR; Liu, H | 1 |
| Chen, W; Li, J; Liu, X; Shi, J; Zhang, Z; Zhao, L; Zhou, Y | 1 |
| Che, J; Chen, D; Dong, X; Li, J; Luo, X; Mi, T; Rao, Z; Tian, T; Wang, H; Wu, Y; Xu, Y; Zhou, Y; Zhou, Z; Zhu, CL | 1 |
| Clarke, IA; Dalgleish, AG; Dredge, K; Marriott, JB; Muller, G; Stirling, D | 1 |
| Bennett, BL; Mercurio, F; Schafer, PH; Stirling, DI; Zeldis, JB | 1 |
| Bartlett, JB; Dalgleish, AG; Dredge, K | 1 |
| Anderson, K; Richardson, P | 1 |
| Chen, RS; Haley, M; Muller, GW; Payvandi, F; Schafer, PH; Stirling, DI; Wu, L; Zhang, LH | 1 |
| Knight, R | 1 |
| Czuczman, MS; Hernandez-Ilizaliturri, FJ; Holkova, B; Ottman, E; Reddy, N | 1 |
| Crane, E; List, A | 1 |
| Anderson, KC; Hideshima, T; Richardson, PG; Schlossman, R | 1 |
| Hussein, MA; Srkalovic, JG; Suppiah, R | 1 |
| Chanan-Khan, A; Porter, CW | 1 |
| Galili, N; Raza, A | 1 |
| Ribatti, D; Vacca, A | 1 |
| Brady, HA; Chan, KW; Chen, R; Corral, LG; Ferguson, GD; Glezer, E; Jensen-Pergakes, K; Lopez-Girona, A; Moutouh-de Parseval, L; Mueller, JH; Muller, GW; Schafer, PH; Verhelle, D; Wong, K | 1 |
| Czuczman, MS; Deeb, G; Hernandez-Ilizaliturri, FJ; Knight, J; Reddy, N; Roth, M; Vaughn, M; Wallace, P | 1 |
| Brady, H; Chan, K; Corral, LG; Ferguson, GD; Glezer, E; Jensen-Pergakes, K; Morris, CL; Moutouh-de Parseval, LA; Muller, G; Verhelle, D | 1 |
| Corral, LG; Fleming, YW; Stein, B; Zhu, D | 1 |
| Asaoku, H; Katayama, Y; Kimura, A; Kubo, T; Kuroda, Y; Munemasa, S; Okikawa, Y; Sakai, A; Shimose, S | 1 |
| Bartlett, JB; Chen, RS; Hariri, RJ; Hughes, CC; Lu, L; Man, HW; Muller, GW; Payvandi, F; Schafer, PH; Stirling, DI; Wu, L; Zhang, LH | 1 |
| Bartlett, JB; Chen, R; Dalgleish, AG; Dredge, K; Galustian, C; Henry, J; Klaschka, D; Labarthe, MC; Meyer, B; Muller, G; Schafer, P; Stirling, D; Todryk, S | 1 |
| Wiernik, PH | 1 |
| Bolton, TB; Dalgleish, AG; Galustian, C; Henry, JY; Laux, H; Liu, WM | 1 |
| Bartlett, JB; Dalgleish, AG; Galustian, C; Henry, JY; Liu, WM; Meyer, B | 1 |
| Brady, HA; Chan, KW; Escoubet-Lozach, L; Gandhi, AK; Jensen-Pergakes, K; Lin, IL; Muller, GW; Schafer, PH; Verhelle, D; Worland, PJ | 1 |
| Hussein, M; Srkalovic, G | 1 |
| Hassett, AC; Lentzsch, S; List, A; Mapara, MY; Monaghan, SA; Moscinski, L; Pal, R; Ragni, MV; Roodman, GD; Schafer, P | 1 |
| Compagnone, R; De Sanctis, JB; Garmendia, J; Mijares, M; Moreno, D; Salazar-Bookaman, M; Suárez, A | 1 |
| de Rezende, LC; Guimarães, MC; Rangel, LB; Silva, IV | 1 |
| Anderson, KC; Bandi, M; Calabrese, E; Cirstea, D; Fabre, C; Görgün, G; Hideshima, T; Hu, Y; Mimura, N; Munshi, N; Nahar, S; Perrone, G; Raje, N; Richardson, P; Santo, L; Soydan, E; Tai, YT | 1 |
| Buadi, F; Detweiler-Short, K; Dingli, D; Dispenzieri, A; Gertz, MA; Hayman, S; Kumar, SK; Kyle, RA; Lacy, MQ; Leung, N; Lust, JA; Rajkumar, SV; Russell, SJ; Zeldenrust, S | 1 |
| Lacy, MQ | 2 |
| Lacy, MQ; Tefferi, A | 1 |
| Schots, R | 1 |
| Galson, DL; Lentzsch, S; Li, S; Mapara, M; Monaghan, SA; Ouyang, H; Pal, R; Schafer, P | 1 |
| Allred, JB; Bergsagel, PL; Buadi, F; Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Hayman, SR; Kumar, S; Lacy, MQ; Laumann, K; Lust, JA; Mandrekar, SJ; Mikhael, JR; Rajkumar, SV; Reeder, C; Roy, V; Russell, SJ; Short, KD; Stewart, AK; Zeldenrust, S | 1 |
| Gauthier, J; Leleu, X; Wémeau, M; Yakoub-Agha, I | 1 |
| Bergsagel, PL; Bjorklund, CC; Braggio, E; Bruins, LA; Chang, XB; Fonseca, R; Orlowski, RZ; Schmidt, JE; Shi, CX; Stewart, AK; Van Wier, S; Zhu, YX | 1 |
| Bodera, P; Stankiewicz, W | 1 |
| Cavo, M | 2 |
| Aerts, JL; Allard, SD; De Keersmaecker, B; Lacor, P; Schots, R; Thielemans, K | 1 |
| Lentzsch, S; Pan, B | 1 |
| Kortuem, KM; Stewart, AK; Zhu, YX | 1 |
| Arima, N; Kawada, H | 1 |
| Agnelli, L; Bolzoni, M; Bonomini, S; Giuliani, N; Guasco, D; Neri, A; Rizzoli, V; Storti, P; Todoerti, K; Toscani, D | 1 |
| Alsina, M; Anand, P; Anderson, KC; Baz, R; Bilotti, E; Chen, M; Doss, D; Ghobrial, IM; Jacques, C; Kelley, SL; Larkins, G; Laubach, J; Loughney, N; McBride, L; Munshi, NC; Nardelli, L; Richardson, PG; Schlossman, R; Siegel, D; Sullivan, D; Wear, S; Zaki, MH | 1 |
| Mahindra, A; Saini, N | 2 |
| Arnulf, B; Attal, M; Avet-Loiseau, H; Benboubker, L; Bréchignac, S; Caillot, D; Decaux, O; Escoffre-Barbe, M; Facon, T; Fermand, JP; Garderet, L; Hennache, B; Hulin, C; Kolb, B; Leleu, X; Macro, M; Marit, G; Mathiot, C; Meuleman, N; Michallet, M; Moreau, P; Pegourie, B; Petillon, MO; Roussel, M; Royer, B; Stoppa, AM; Thielemans, B; Traulle, C | 1 |
| Dalgleish, AG; Dasgupta, P; Galustian, C; Henry, JY; Labarthe, MC; Meyer, B | 1 |
| Ahluwalia, R; Carson, KR; Cox, DP; Fiala, MA; Jaenicke, M; Moliske, CC; Stockerl-Goldstein, KE; Tomasson, MH; Trinkaus, KM; Vij, R; Wang, TF; Wildes, TM | 1 |
| Forsberg, PA; Mark, TM | 1 |
| Erskine, L; Figg, WD; Greig, NH; Mahony, C; Niven, J; Vargesson, N | 1 |
| Ishida, T | 1 |
| Avet-Loiseau, H; Bjorklund, C; Calle, Y; Chelliah, R; Chopra, R; Gandhi, AK; Lentzsch, S; Lopez-Girona, A; Madan, A; Mendy, D; Ning, Y; Orlowski, RZ; Schafer, P; Schey, SA; Thakurta, A; Waldman, MF | 1 |
| Ando, H; Chopra, R; Conklin, T; Daniel, TO; Gandhi, AK; Handa, H; Havens, CG; Ito, T; Kang, J; Klippel, A; Ning, Y; Schafer, PH; Thakurta, A; Waldman, MF; Wu, L | 1 |
| Anderson, KC; Bahlis, N; Baz, R; Belch, A; Chen, C; Chen, M; Hofmeister, CC; Jacques, C; Jagannath, S; Jakubowiak, A; Lacy, M; Lentzsch, S; Lonial, S; Matous, J; Mikhael, J; Raje, N; Richardson, PG; Shustik, C; Siegel, DS; Song, K; Vesole, D; Vij, R; Yu, Z; Zaki, MH | 1 |
| Kyle, RA; Rajkumar, SV | 1 |
| Agarwal, S; Eddins, MJ; Kodrasov, MP; Kumar, S; LaRocque, JP; Marblestone, JG; Mattern, MR; Nicholson, B; Sterner, DE; Wu, J | 1 |
| Bergsagel, PL; Braggio, E; Bruins, LA; Champion, MD; Chang, XB; Fonseca, R; Jedlowski, P; Kortuem, KM; Lacy, M; Langlais, P; LaPlant, B; Laumann, K; Luo, M; Mikhael, J; Schmidt, JE; Shi, CX; Stewart, AK; Zhu, YX | 1 |
| Aerts, JL; Corthals, J; De Keersmaecker, B; Fostier, K; Heirman, C; Schots, R; Thielemans, K; Wilgenhof, S | 1 |
| Acker, V; Beckwith, RE; Böhm, K; Cavadini, S; Fischer, ES; Forrester, WC; Harper, JW; Hassiepen, U; Hild, M; Jenkins, JL; Lingaraju, GM; Lydeard, JR; Nagel, J; Ottl, J; Schebesta, M; Schirle, M; Serluca, F; Stadler, MB; Thomä, NH; Tichkule, RB; Yang, H | 1 |
| Bjorklund, CC; Corchete, LA; Couto, S; Delgado, M; Díaz-Rodríguez, E; Fernández-Lázaro, D; Garayoa, M; García-Gómez, A; Gutiérrez, NC; López-Corral, L; Mateos, MV; Montero, JC; Ocio, EM; Paíno, T; Pandiella, A; San-Miguel, JF; San-Segundo, L; Wang, M | 1 |
| Kumar, S; Singla, A | 1 |
| Birgegård, G | 1 |
| Bories, C; Facon, T; Fouquet, G; Guidez, S; Herbaux, C; Javed, S; Leleu, X; Renaud, L | 1 |
| Bátorová, A; Mistrík, M; Roziaková, L | 1 |
| Anderson, KC; Dimopoulos, MA; Moreau, P; Richardson, PG | 1 |
| Liu, G; Sheng, Z | 1 |
| Colson, K | 1 |
| Camarero, J; Flores, B; Gisselbrecht, C; Hanaizi, Z; Hemmings, R; Laane, E; Pignatti, F; Salmonson, T; Sancho-Lopez, A | 1 |
| Foster, MC; Zeidner, JF | 1 |
| Adler, AI; Burke, MJ; George, E | 1 |
| Anderson, KC; Cottini, F; Gorgun, G; Hideshima, T; Jakubikova, J; Mimura, N; Munshi, NC; Ohguchi, H; Richardson, PG; Tai, YT | 1 |
| Amantangelo, MD; Barnes, L; Bjorklund, C; Breider, M; Cai, T; Chiu, H; Chopra, R; Couto, S; Daniel, TO; Fontanillo, C; Gandhi, AK; Hagner, PR; Havens, CG; Kang, J; Khambatta, G; Klippel, A; Kosek, J; Lopez-Girona, A; Lu, G; Man, HW; Narla, RK; Pourdehnad, M; Raymon, H; Rychak, E; Schafer, PH; Thakurta, A; Trotter, M; Waldman, M; Wang, M | 1 |
| Chaudhary, PM; Gopalakrishnan, R; Matta, H; Tolani, B; Triche, T | 1 |
| Amatya, R; Belch, A; Dimopoulos, M; Gibson, CJ; Jacques, C; Moreau, P; Palumbo, A; San Miguel, J; Schey, S; Song, KW; Sonneveld, P; Sternas, L; Weisel, K; Yu, X; Zaki, M | 1 |
| Chen-Kiang, S; He, X; Huang, X; Jaffrey, SR; Jiang, X; Liu, Y; Xu, G; Zhou, Y | 1 |
| Boise, LH; Kaufman, J; Lonial, S | 1 |
| Amatangelo, M; Bjorklund, CC; Breider, M; Chopra, R; Couto, S; Daniel, TO; Gandhi, AK; Hagner, PR; Havens, CG; Kang, J; Klippel, A; Lu, L; Ning, Y; Ren, Y; Thakurta, AG; Wang, M | 1 |
| Cong, Z; Song, X; Wilson, K | 1 |
| Binder, G; Grigorian, M; Lee, C; Nolan, R; Rice, G | 1 |
| Hajek, R; Jelinek, T; Kufova, Z | 1 |
| Dubey, P; Gemechu, Y; Kishimoto, T; Millrine, D; Miyata, H; Nakahama, T; Nyati, K; Ripley, B; Tei, M | 1 |
| Bjorklund, CC; Cathers, BE; Chopra, R; Daniel, TO; Gandhi, AK; Leisten, J; Lopez-Girona, A; Lu, L; Mendy, D; Miller, K; Narla, RK; Ning, Y; Orlowski, RZ; Raymon, HK; Rychak, E; Shi, T; Thakurta, A | 1 |
| Rochau, U; Siebert, U; Weger, R; Willenbacher, E; Willenbacher, W | 1 |
| Anderson, KC; Attal, M; Avet-Loiseau, H; Bladé, J; Caers, J; Chng, WJ; Durie, BG; Einsele, H; Goldschmidt, H; Hillengass, J; Kyle, RA; Lonial, S; Mateos, MV; Moreau, P; Orlowski, R; Palumbo, A; San Miguel, J; Siegel, D; Sonneveld, P; Usmani, S; van de Donk, NW | 1 |
| Borg, S; Elvidge, J; Hansson, M; Lee, D; Nahi, H; Persson, U | 1 |
| Bassermann, F; Eichner, R; Einsele, H; Fernández-Sáiz, V; Garz, AK; Germing, U; Götze, KS; Haass, C; Heider, M; Jacobs, L; Keller, U; Knop, S; Knorn, AM; Kuster, B; Langer, C; Lemeer, S; Peschel, C; Platzbecker, U; Rudelius, M; Schmid, B; Slawska, J; Targosz, BS; van Bebber, F | 1 |
| Baladandayuthapani, V; Dawson, CW; Iempridee, T; Jones, RJ; Kenney, SC; Lee, HC; Lin, HC; Mertz, JE; Orlowski, RZ; Shah, JJ; Wang, X; Weber, DM | 1 |
| Krönke, J; Lindner, S | 1 |
| Dimopoulos, MA; Gavriatopoulou, M; Kastritis, E; Terpos, E | 1 |
| Abudayyeh, A; Doshi, M; Edeani, A; Glezerman, IG; Jhaveri, KD; Monga, D; Rosner, M; Wanchoo, R | 1 |
| Abe, M; Aihara, K; Amachi, R; Bat-Erdene, A; Cui, Q; Endo, I; Fujii, S; Harada, T; Iwasa, M; Kagawa, K; Matsumoto, T; Miki, H; Nakamura, S; Oda, A; Ozaki, S; Sogabe, K; Teramachi, J; Yoshida, S | 1 |
| Criado, G; Delgado, M; Diaz de la Guardia, R; García-Herrero, CM; Gonzalez-Rey, E; Lavoie, JR; Lopez-Millan, B; Menendez, P; O'Valle, F; Roca-Ho, H; Rosu-Myles, M | 1 |
| Lentzsch, S; Raza, S; Safyan, RA | 1 |
| Holstein, SA; McCarthy, PL | 1 |
| Goldschmidt, H; Kellermann, L; Knauf, W; Kohnke, J; Merz, M; Poenisch, W; Tischler, HJ | 1 |
| Al, MJ; Albuquerque de Almeida, F; Armstrong, N; Büyükkaramikli, NC; de Groot, S; Fayter, D; Kleijnen, J; Stirk, L; Wolff, R; Worthy, G | 1 |
| Asmar, F; Christensen, J; Dimopoulos, K; Fibiger Munch-Petersen, H; Gimsing, P; Grønbaek, K; Hermansen, NEU; Liang, G; O'Connel, C; Sjö, L; Sommer Kristensen, L; Søgaard Helbo, A | 1 |
| Dimopoulos, MA; Fotiou, D; Gavriatopoulou, M; Kanellias, N; Kastritis, E; Migkou, M; Ntanasis-Stathopoulos, I; Roussou, M; Terpos, E; Ziogas, DC | 1 |
| Belch, A; Diels, J; Ito, T; Oriol, A; Van Sanden, S; Vogel, M | 1 |
| Campioni, M; DeCosta, L; Fink, L; Flinois, A; Gazzola, C; Gonzalez-McQuire, S; Leleu, H; Mennini, FS; Schoen, P; Yong, K | 1 |
| Schmidt, C | 1 |
| Anderson, SM; Beck, B; Lockhorst, R; Ngorsuraches, S; Sterud, S | 1 |
| Admojo, L; Darcy, PK; Davenport, AJ; Fairlie, DP; Gherardin, NA; Godfrey, DI; Harrison, SJ; Jenkins, MR; Kedzierska, K; Loh, L; McCluskey, J; Neeson, PJ; Prince, HM; Quach, H; Richardson, K; Ritchie, DS; Rogers, A; Uldrich, AP | 1 |
| van de Donk, NWCJ | 2 |
| Ben Amara, A; Benyamine, A; Castanier, C; Castellano, R; Collette, Y; Fauriat, C; Fournié, JJ; Goubard, A; Granjeaud, S; Le Roy, A; Mege, JL; Olive, D; Orlanducci, F; Pont, F; Prébet, T; Riccardi, F; Vey, N | 1 |
| Dimopoulos, MA; Gavriatopoulou, M; Migkou, M; Terpos, E | 1 |
| Burslem, GM; Crews, CM; Cromm, PM; Jaime-Figueroa, S; Morgan, A; Ottis, P; Toure, M | 1 |
| Gottwein, E; Manzano, M; Patil, A | 1 |
| Nohgawa, M; Oka, S; Ono, K | 1 |
| Tomlinson, R | 1 |
| Abdulrahman, W; Bunker, RD; Ebert, BL; Liddicoat, BJ; Mikkelsen, T; Petzold, G; Renneville, A; Sievers, QL; Słabicki, M; Thomä, NH | 1 |
| Batchelor, TT; Grommes, C; Nayak, L; Tun, HW | 1 |
| Caballero García, A; Córdova Martínez, A; Fernández-Lázaro, CI; Fernández-Lázaro, D | 1 |
| Blin, N; Bonnet, A; Chevallier, P; Dubruille, V; Garnier, A; Gastinne, T; Guillaume, T; Jullien, M; Le Bourgeois, A; Le Gouill, S; Lok, A; Mahé, B; Moreau, P; Peterlin, P; Tessoulin, B; Touzeau, C; Trudel, S | 1 |
| Auclair, D; Bahlis, NJ; Barwick, BG; Boise, LH; Dhodapkar, MV; Gupta, VA; Hofmeister, CC; Jaye, DL; Kaufman, JL; Keats, JJ; Lonial, S; Neri, P; Nooka, AK; Vertino, PM | 1 |
| Boise, LH; Gleason, C; Gupta, VA; Heffner, LT; Joseph, NS; Kaufman, JL; Lonial, S; Nooka, AK | 1 |
| Gay, F; Mina, R | 1 |
| Kim, GW; Kwon, SH; Lee, DH; Ryu, HW; Won, HR; Yeon, SK | 1 |
| Furukawa, Y; Hagiwara, S; Hori, M; Iha, H; Izumi, T; Kikuchi, J; Koyama, D; Kuroda, Y; Suzuki, A; Toyama-Sorimachi, N; Yasui, H | 1 |
| Mo, CC; Richardson, PG | 1 |
| Agajanian, R; Agarwal, A; Bahlis, NJ; Chung, W; Kaya, H; Malek, E; Mouro, J; Pierceall, WE; Samaras, C; Schiller, GJ; Sebag, M; Seet, CS; Siegel, DS; Song, KW; Srinivasan, S; Stockerl-Goldstein, K; Talamo, G; Zafar, F | 1 |
| Amatangelo, M; Bjorklund, CC; Chiu, H; Couto, S; Flynt, JE; Kang, J; Katz, M; Ortiz, M; Pierceall, W; Polonskaia, A; Ren, Y; Thakurta, A; Towfic, F; Wang, M | 1 |
| Chen, P; Wang, T; Wu, Z; Zhang, F; Zhang, H; Zhang, J; Zhou, J | 1 |
| Delimpasi, S; Dialoupi, I; Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Fotiou, D; Gavriatopoulou, M; Giannouli, S; Kanellias, N; Kastritis, E; Migkou, M; Mparmparousi, D; Ntanasis-Stathopoulos, I; Roussou, M; Spyropoulou-Vlachou, M; Terpos, E; Tsirigotis, P; Xirokosta, A; Ziogas, DC | 1 |
| Cahn, JY; Courby, S; Deteix, C; Larabi, A; Meunier, M; Schacherer, M | 1 |
| Choi, CW; Eom, HS; Kang, HJ; Kim, I; Kim, JS; Kim, K; Kim, MK; Kim, SJ; Lee, HS; Lee, JJ; Lim, SN; Min, CK; Mun, YC; Shin, HJ; Suh, C; Yoon, DH; Yoon, SS | 1 |
| Anderson Tvedt, TH; Bruserud, Ø; Ersvær, E; Rundgren, IM; Ryningen, A | 1 |
| Chung, DJ; Diamond, B; Lesokhin, AM; Maclachlan, K; Ola Landgren, C | 1 |
| Lesokhin, AM; Wills, B; Wudhikarn, K | 1 |
| Aschan, J; Pour, L; Robak, P; Schjesvold, F; Sonneveld, P | 1 |
| Agis, H; Blank, A; Blau, IW; Chatterjee, M; Einsele, H; Engelhardt, M; Ferstl, B; Goldschmidt, H; Griese, J; Härtle, S; Jarutat, T; Peschel, C; Raab, MS; Röllig, C; Schub, N; Weirather, J; Weisel, K; Winderlich, M | 1 |
| Cornell, RF; Engelhardt, BG; Goldhaber, SZ; Hall, R; Harrell, S; Jagasia, M; Moslehi, J; Piazza, G; Rubinstein, SM; Wyatt, H | 1 |
| Acosta-Rivera, M; Agarwal, A; Anz, B; Bahlis, NJ; Bar, M; Berdeja, J; Chung, W; Fonseca, G; Ganguly, S; Matous, J; Pierceall, WE; Quick, D; Reece, D; Samaras, C; Schiller, GJ; Sebag, M; Seet, CS; Siegel, DS; Song, K; Talamo, G; Zafar, F | 1 |
| Almodovar-Rivera, CM; Nie, X; Tang, W; Wang, B; Wu, H; Xie, H; Yang, K; Zhao, Y | 1 |
| Jeon, YH; Kim, GW; Kwon, SH; Lee, DH; Lee, SW; Won, HR; Yeon, SK; Yoo, J | 1 |
| Chinen, Y; Fujibayashi, Y; Gütschow, M; Horiike, S; Isa, R; Kobayashi, T; Kuroda, J; Kuwahara-Ota, S; Matsumura-Kimoto, Y; Mizuno, Y; Nishiyama, D; Shimura, Y; Steinebach, C; Takimoto-Shimomura, T; Taniwaki, M; Tsukamoto, T; Yamaguchi, J | 1 |
| Bittrich, M; Danhof, S; Einsele, H; Gisslinger, B; Gisslinger, H; Hefner, J; Hose, D; Knop, S; Krauth, MT; Schoder, R; Schreder, M; Strifler, S | 1 |
| Anderson, LD; Biyukov, T; Casal, E; Corso, A; Dimopoulos, M; Dürig, J; Engelhardt, M; Jenner, M; Moreau, P; Nguyen, TV; Pavic, M; Peluso, T; Richardson, P; Salomo, M; San-Miguel, J; Sonneveld, P; Srinivasan, S; Weisel, K; White, D; Yu, X | 1 |
| Anderson, KC; Arvedson, T; Cho, SF; Friedrich, M; Hsieh, PA; Li, Y; Lin, L; Matthes, K; Munshi, N; Tai, YT; Wahl, J; Wen, K; Xing, L; Yu, T | 1 |
| Agarwal, A; Amatangelo, MD; Bahlis, NJ; Chung, W; Neri, P; Parekh, S; Pierceall, WE; Rahman, A; Serbina, N; Siegel, DS; Thakurta, A; Van Oekelen, O; Young, M | 1 |
| Asatsuma-Okumura, T; Handa, H; Ito, T; Kishi, T; Kizaki, M; Mizutome, H; Momose, S; Murase, Y; Shimizu, N; Suwa, T; Tateno, S; Yamaguchi, Y; Yamamoto, J | 1 |
| Beilhack, A; Brandl, A; Köpff, S; Krönke, J; Lindner, S; Ng, YLD; Röhner, L; Scheffold, A | 1 |
| Berenson, JR; Eades, B; Emamy-Sadr, M; Regidor, B; Spektor, TM; Swift, R; Tarhini, F | 1 |
| Jiang, X; Kan, W; Li, J; Li, Y; Mi, T; Wang, Y; Xu, G; Zhou, Y | 1 |
| Ansari-Pour, N; Bahlis, N; Chamberlain, PP; Dhiman, P; Flynt, E; Gooding, S; Hirst, M; Neri, P; Ortiz Estévez, M; Ramasamy, K; Rozelle, D; Thakurta, A; Towfic, F; Tsai, KT; Vyas, P | 1 |
| Barchnicka, A; Bednarczyk, M; Grosicka, O; Grosicki, S | 1 |
| Chari, A; Delea, TE; Hagiwara, M; Kee, A; Madduri, D; Parikh, K; Pelletier, C | 1 |
| Andriani, A; Annibali, O; Antolino, G; Cantonetti, M; Cimino, G; Coppetelli, U; De Rosa, L; De Stefano, V; di Toritto, TC; La Verde, G; Petrucci, MT; Piciocchi, A; Rizzo, M; Siniscalchi, A; Vozella, F; Za, T | 1 |
| Bernabei, L; Cohen, AD; Garfall, AL; Gonzalez, VE; June, CH; Lacey, SF; Levine, BL; Melenhorst, JJ; Milone, MC; Plesa, G; Stadtmauer, EA; Tian, L; Vogl, DT; Waxman, A; Young, RM | 1 |
| Blevins, F; Hughes, D; Lerner, A; Milrod, CJ; Sanchorawala, V; Sarosiek, S; Sloan, JM | 1 |
| Aslam, M; Atenafu, EG; Cherniawsky, H; Gul, E; Jimenez-Zepeda, VH; Kotb, R; LeBlanc, R; Louzada, ML; Masih-Khan, E; McCurdy, A; Reece, DE; Reiman, A; Sebag, M; Song, K; Stakiw, J; Venner, CP; White, D | 1 |
| Ciotkowska, A; Gratzke, C; Hennenberg, M; Huang, R; Li, B; Rutz, B; Sauckel, C; Stief, CG; Tamalunas, A; Wang, R | 1 |
| Lewis, DJ; Mueller, M | 1 |
| Hasegawa, A; Ishizawa, M; Kannagi, M; Katagiri, K; Kondo, N; Masuda, T; Nagano, Y; Yoneda, T | 1 |
| Chim, CS; Kumar, S; Kwong, YL; Ngai, C; Wong, VKC | 1 |
| Anderson, LD; Beksac, M; Corso, A; Dimopoulos, M; Dürig, J; Engelhardt, M; Galli, M; Grote, L; Jenner, M; Jiang, R; Kanate, AS; Larocca, A; Liberati, AM; Lindsay, J; Moreau, P; Oriol, A; Pavic, M; Peluso, T; Richardson, PG; Robak, P; Rodriguez-Otero, P; Salomo, M; Schjesvold, F; Sonneveld, P; Vural, F; Weisel, K; White, D; Yagci, M | 1 |
| Bova-Solem, M; Carlisle, D; Efebera, YA; Hassoun, H; Laubach, JP; McCarthy, PL; Mulkey, F; Richardson, PG; Santo, K; Suman, VJ; Tuchman, SA; Voorhees, PM | 1 |
| D'Rozario, J; Estell, J; Ho, PJ; Kalff, A; Kemp, R; Kennedy, N; Khong, T; Mitchell, AJ; Mollee, P; Norton, S; Quach, H; Ramachandran, M; Reynolds, J; Spencer, A; Taylor, K | 1 |
| Adelman, K; Amaka, S; de Leval, L; Donaldson, NL; Donovan, KA; Duffy, J; Fischer, ES; Gaulard, P; Hagner, PR; Heavican-Foral, TB; Iqbal, J; Jain, S; Jones, MK; Koch, R; Liu, H; Nelson, GM; Ng, SY; Nirmal, AJ; Nowak, RP; Powers, F; Stevenson, KE; Thakurta, A; Trevisani, C; Weinstock, DM; Wu, G; Wu, W; Xu, R; Yang, L | 1 |
| Alekseeva, Y; Bakker, NA; Byrne, C; Coriu, D; Delimpasi, S; Dimopoulos, MA; Doronin, V; Hájek, R; Harmenberg, J; Lazzaro, A; Legiec, W; Liberati, AM; Maisnar, V; Masszi, T; Mateos, MV; Mikala, G; Minarik, J; Moody, V; Pour, L; Richardson, PG; Robak, P; Rosiñol, L; Salogub, G; Schjesvold, FH; Sonneveld, P; Špička, I; Symeonidis, A; Thuresson, M | 1 |
| Darif, M; Demarquette, H; Dimopoulos, MA; Doronin, V; Du, J; Fenk, R; Kumar, S; Labotka, R; Lee, C; Leleu, X; Levin, MD; Mellqvist, UH; Montes, YG; Pompa, A; Quach, H; Ramasamy, K; Sati, H; Schjesvold, F; Vinogradova, O; Vorog, A | 1 |
| Acosta-Rivera, M; Agarwal, A; Anz, B; Bahlis, NJ; Bar, M; Berdeja, J; Chung, W; Fonseca, G; Ganguly, S; Lee, K; Matous, J; Mouro, J; Quick, D; Reece, D; Samaras, C; Schiller, GJ; Sebag, M; Seet, CS; Siegel, DS; Song, K | 1 |
| Brillac, C; Fau, JB; Gaudel-Dedieu, N; Koiwai, K; Nguyen, L; Rachedi, F; Sebastien, B; Semiond, D; Thai, HT; van de Velde, H; Veyrat-Follet, C | 1 |
| Chung, W; Iida, S; Iwasaki, H; Kuroda, J; Kuwayama, S; Lee, K; Matsue, K; Matsumoto, M; Nishio, M; Sugiura, I; Sunami, K | 1 |
| Gogia, A; Gupta, R; Kumar, L; Kumar, S; Malik, PS; Pathak, N; Prasad, CP; Sahoo, RK; Sharma, A | 1 |
| Bai, H; Fang, BJ; Fu, WJ; Liao, AJ; Lu, J; Niu, T; Wang, YF; Zhao, HG | 1 |
| Afari, J; Berenson, JR; Bessudo, A; Cohen, A; Eades, BM; Eshaghian, S; Gabrail, N; Jhangiani, H; Kim, C; Kim, S; Kubba, S; Neidhart, JD; Spektor, TM; Swift, RA; Turner, C; Vescio, R | 1 |
| Das, P; Dimopoulos, MA; Dytfeld, D; Grosicki, S; Hori, M; Jou, YM; LeBlanc, R; Leleu, X; Moreau, P; Popa McKiver, M; Raab, MS; Richardson, PG; San-Miguel, J; Suzuki, K; Takezako, N; Yao, D | 1 |
| Alizadeh, H; Illés, Á; Lovas, S; Mikala, G; Obajed Al-Ali, N; Plander, M; Rajnics, P; Szemlaky, Z; Szita, V; Varga, G; Váróczy, L | 1 |
| Chen, H; Xu, W; Xu, Y; Yu, J; Zhou, F; Zhou, Y | 1 |
| Bekri, S; Cho, HJ; Costa, LJ; Hamidi, H; Neparidze, N; Nielsen, TG; Raval, A; Sareen, R; Vij, R; Wassner-Fritsch, E; Wong, S | 1 |
| Davies, FE; Dhanasiri, S; Le Nouveau, P; Leleu, X; Vogel, P; Weisel, K | 1 |
| Baldini, L; Beksac, M; Bila, J; Boccadoro, M; Carson, R; Delimpasi, S; Dimopoulos, MA; Einsele, H; Kampfenkel, T; Katodritou, E; Kosh, M; Liu, W; Mateos, MV; Moreau, P; Orfanidis, I; Oriol, A; Sonneveld, P; Symeonidis, A; Terpos, E; Tran, N; Wang, J | 1 |
49 review(s) available for lenalidomide and pomalidomide
| Article | Year |
|---|---|
A review on the treatment of multiple myeloma with small molecular agents in the past five years.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Combined Modality Therapy; Deubiquitinating Enzymes; Drug Development; Drug Resistance; Histone Deacetylases; Humans; Ikaros Transcription Factor; Immunomodulating Agents; Models, Molecular; Morpholines; Multiple Myeloma; Phthalimides; Piperidones; Proteasome Inhibitors; Treatment Outcome; Ubiquitin-Protein Ligases | 2022 |
Potential new therapeutics for Waldenstrom's macroglobulinemia.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adjuvants, Immunologic; Clinical Trials as Topic; Cyclic Nucleotide Phosphodiesterases, Type 4; Cytokines; Enzyme Inhibitors; Humans; JNK Mitogen-Activated Protein Kinases; Lenalidomide; Ligases; MAP Kinase Kinase 4; Mitogen-Activated Protein Kinase Kinases; Thalidomide; Ubiquitin-Protein Ligases; Waldenstrom Macroglobulinemia | 2003 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Neoplasms; T-Lymphocytes; Thalidomide; Tumor Necrosis Factor-alpha | 2004 |
IMiDs: a novel class of immunomodulators.
Topics: Angiogenesis Inhibitors; Clinical Trials, Phase I as Topic; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Thalidomide | 2005 |
Immunomodulatory drugs.
Topics: Humans; Immunosuppressive Agents; Interleukin-12; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Multiple Myeloma; Myelodysplastic Syndromes; Neovascularization, Pathologic; T-Lymphocytes; Thalidomide | 2005 |
New treatments for multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Oxides; Pyrazines; Thalidomide | 2005 |
Immunomodulatory analogues of thalidomide in the treatment of multiple myeloma.
Topics: Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Thalidomide | 2006 |
Immunomodulating drugs for chronic lymphocytic leukaemia.
Topics: Aged; Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Cytokines; Down-Regulation; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Middle Aged; Thalidomide | 2006 |
Immunomodulatory drugs in myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Animals; Apoptosis; Blood Transfusion; Cell Lineage; Cells, Cultured; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Cytokines; Drug Evaluation, Preclinical; Drugs, Investigational; Erythrocyte Transfusion; Erythropoiesis; Female; Hematopoietic Stem Cells; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; NF-kappa B; Pilot Projects; Thalidomide; Thrombocytopenia; Tumor Necrosis Factor-alpha | 2006 |
Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Combined Modality Therapy; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Salvage Therapy; Thalidomide; Venous Thromboembolism; Young Adult | 2009 |
Immunomodulatory compounds (IMiDs) in the treatment of multiple myeloma.
Topics: Clinical Trials, Phase III as Topic; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Thalidomide | 2009 |
Pharmacological properties of thalidomide and its analogues.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Humans; Immunologic Factors; Lenalidomide; Patents as Topic; Thalidomide | 2010 |
Regulatory T cell as a target for cancer therapy.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Cyclophosphamide; Humans; Immunotherapy; Lenalidomide; Mice; Models, Animal; Myeloablative Agonists; Neoplasms; T-Lymphocytes, Regulatory; Thalidomide; Vidarabine | 2010 |
New immunomodulatory drugs in myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neutropenia; Thalidomide; Treatment Outcome | 2011 |
Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Primary Myelofibrosis; Protease Inhibitors; Pyrazines; Thalidomide | 2011 |
[IMiDs in hematology].
Topics: Chronic Disease; Hematologic Neoplasms; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphoid; Lymphoma, Non-Hodgkin; Multiple Myeloma; Myelodysplastic Syndromes; Primary Myelofibrosis; Thalidomide; Waldenstrom Macroglobulinemia | 2011 |
Immunomodulatory properties of thalidomide analogs: pomalidomide and lenalidomide, experimental and therapeutic applications.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Drug Evaluation, Preclinical; Humans; Immunomodulation; Lenalidomide; Neoplasms; Patents as Topic; Thalidomide | 2011 |
The application and biology of immunomodulatory drugs (IMiDs) in cancer.
Topics: Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms; Neoplasms, Second Primary; Thalidomide | 2012 |
Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma.
Topics: Adaptor Proteins, Signal Transducing; Gene Expression; Humans; Immunologic Factors; Interferon Regulatory Factors; Lenalidomide; Multiple Myeloma; Peptide Hydrolases; Teratogens; Thalidomide; Ubiquitin-Protein Ligases | 2013 |
[Update on treatment of multiple myeloma: including myeloma kidney and molecular targeting drugs].
Topics: Boronic Acids; Bortezomib; Drug Design; Humans; Immunologic Factors; Kidney Neoplasms; Lenalidomide; Molecular Targeted Therapy; Multiple Myeloma; Oligopeptides; Plasmacytoma; Pyrazines; Thalidomide | 2012 |
Novel immunomodulatory compounds in multiple myeloma.
Topics: Angiogenesis Inhibitors; Clinical Trials as Topic; Disease-Free Survival; Humans; Immunologic Factors; Lenalidomide; Molecular Structure; Multiple Myeloma; Thalidomide | 2013 |
Therapeutic strategies for the treatment of multiple myeloma.
Topics: ADP-ribosyl Cyclase 1; Antineoplastic Agents; Boronic Acids; Bortezomib; Cytokines; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Homeostasis; Humans; Immune System; Immunotherapy; Lenalidomide; Multiple Myeloma; Oligopeptides; Prognosis; Protease Inhibitors; Pyrazines; Recurrence; Syndecan-1; Thalidomide | 2013 |
Discovery of Therapeutic Deubiquitylase Effector Molecules: Current Perspectives.
Topics: Animals; Catalytic Domain; Drug Design; Drug Screening Assays, Antitumor; Fluorescence Resonance Energy Transfer; Humans; Lenalidomide; Ligands; Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Conformation; Thalidomide; Ubiquitin; Ubiquitin-Protein Ligases; Ubiquitin-Specific Proteases | 2014 |
Current advances in non-proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myeloma.
Topics: Antibodies, Monoclonal; Histone Deacetylase Inhibitors; Humans; Lenalidomide; Multiple Myeloma; Recurrence; Thalidomide; TOR Serine-Threonine Kinases | 2011 |
Does anything work for anaemia in myelofibrosis?
Topics: Androgens; Anemia; Blood Transfusion; Erythropoietin; Hematinics; Humans; Immunosuppressive Agents; Interferons; Lenalidomide; Nitriles; Oxymetholone; Primary Myelofibrosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Thalidomide | 2014 |
Pomalidomide for multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Pyrazines; Thalidomide | 2014 |
[Pomalidomide in the treatment of relapsed and refractory multiple myeloma].
Topics: Administration, Oral; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Pyrazines; Thalidomide | 2014 |
Current treatment landscape for relapsed and/or refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulins; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Peripheral Nervous System Diseases; Pyrazines; Thalidomide; Treatment Outcome | 2015 |
Pooled analysis of the reports of pomalidomide after failure of lenalidomide and (or) bortezomib for multiple myeloma.
Topics: Age Factors; Aged; Aged, 80 and over; Bortezomib; Clinical Trials as Topic; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Thalidomide | 2016 |
Treatment-related symptom management in patients with multiple myeloma: a review.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug-Related Side Effects and Adverse Reactions; Humans; Immunologic Factors; Immunomodulation; Lenalidomide; Multiple Myeloma; Oligopeptides; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Quality of Life; Thalidomide | 2015 |
The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Europe; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Survival Rate; Thalidomide | 2015 |
Immunomodulatory Drugs: IMiDs in Acute Myeloid Leukemia (AML).
Topics: Clinical Trials as Topic; Humans; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Thalidomide; Treatment Outcome | 2017 |
Immunomodulatory drugs in AL amyloidosis.
Topics: Amyloidosis; Animals; Humans; Immunoglobulin Light Chains; Immunologic Factors; Lenalidomide; Salvage Therapy; Thalidomide | 2016 |
The molecular mechanism of thalidomide analogs in hematologic malignancies.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Casein Kinase I; Gene Expression Regulation, Neoplastic; Humans; Ikaros Transcription Factor; Interleukin-2; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Peptide Hydrolases; Protein Binding; Proteolysis; Signal Transduction; Thalidomide; Ubiquitin-Protein Ligases; Ubiquitination | 2016 |
Current treatments for renal failure due to multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Oligopeptides; Renal Insufficiency; Thalidomide | 2016 |
Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Everolimus; Humans; Imidazoles; Immunologic Factors; Indoles; Kidney Diseases; Lenalidomide; Multiple Myeloma; Nivolumab; Oligopeptides; Oximes; Proteasome Inhibitors; Protein Kinase Inhibitors; Sulfonamides; Thalidomide; Vemurafenib | 2017 |
Immunomodulatory Drugs (IMiDs) in Multiple Myeloma.
Topics: Clinical Trials as Topic; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Proteasome Inhibitors; Quality of Life; Thalidomide; Venous Thromboembolism | 2017 |
Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience.
Topics: Humans; Immunologic Factors; Immunomodulation; Lenalidomide; Multiple Myeloma; Thalidomide | 2017 |
Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cost-Benefit Analysis; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recurrence; Technology Assessment, Biomedical; Thalidomide | 2018 |
Immunomodulatory effects of CD38-targeting antibodies.
Topics: Adenosine; ADP-ribosyl Cyclase 1; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes, Regulatory; B7-H1 Antigen; Humans; Immunologic Factors; Lenalidomide; Membrane Glycoproteins; Multiple Myeloma; Myeloid-Derived Suppressor Cells; Programmed Cell Death 1 Receptor; T-Lymphocytes, Regulatory; Thalidomide | 2018 |
Optimizing therapy in bortezomib-exposed patients with multiple myeloma.
Topics: Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2018 |
Introduction of novel agents in the treatment of primary CNS lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aminopyridines; Antineoplastic Agents, Immunological; Burkitt Lymphoma; Central Nervous System Neoplasms; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Rituximab; Salvage Therapy; Thalidomide; Toll-Like Receptors; TOR Serine-Threonine Kinases; Tumor Escape | 2019 |
[Immunomodulator drugs for the treatment of multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Immunologic Factors; Immunomodulation; Lenalidomide; Multiple Myeloma; Thalidomide | 2018 |
Maintenance therapy and need for cessation studies in multiple myeloma: Focus on the future.
Topics: Adaptive Clinical Trials as Topic; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Glycine; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Neoplasm, Residual; Oligopeptides; Thalidomide; Transplantation, Autologous; Withholding Treatment | 2020 |
Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action.
Topics: Antibodies, Bispecific; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Drug Administration Schedule; Humans; Immunoconjugates; Lenalidomide; Multiple Myeloma; Neoplasm, Residual; Recurrence; Survival Analysis; Thalidomide | 2020 |
Sequencing multiple myeloma therapies with and after antibody therapies.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; High-Throughput Nucleotide Sequencing; Humans; Immunotherapy; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide | 2020 |
Implementation of a Pregnancy Prevention Programme (PPP) with a Controlled Distribution System (CDS) for the Generic Teratogenic Phthalimides Thalidomide, Lenalidomide and Pomalidomide.
Topics: Child; Female; Humans; Infant, Newborn; Lenalidomide; Phthalimides; Pregnancy; Teratogens; Thalidomide | 2021 |
Comparative efficacy of novel-drugs combined therapeutic regimens on relapsed/refractory multiple myeloma: a network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Network Meta-Analysis | 2023 |
A Meta-Analysis of the Efficacy of Pomalidomide-Based Regimens for the Treatment of Relapsed/Refractory Multiple Myeloma After Lenalidomide Exposure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2023 |
29 trial(s) available for lenalidomide and pomalidomide
| Article | Year |
|---|---|
Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells.
Topics: Adjuvants, Immunologic; Adult; Aged; Antibodies, Monoclonal; Antigens, CD; CD3 Complex; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cells, Cultured; Enzyme-Linked Immunosorbent Assay; Female; Humans; Inflammation; Lenalidomide; Lipopolysaccharides; Lymphocyte Activation; Male; Middle Aged; Neoplasms; Phosphodiesterase Inhibitors; Receptors, Interleukin-2; Receptors, Tumor Necrosis Factor; Receptors, Tumor Necrosis Factor, Type II; Signal Transduction; Solubility; Thalidomide; Tumor Necrosis Factor-alpha | 2002 |
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Survival Analysis; Thalidomide; Treatment Failure; Treatment Outcome | 2011 |
Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Failure; Treatment Outcome | 2013 |
Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; France; Humans; Lenalidomide; Medical Oncology; Middle Aged; Multiple Myeloma; Pyrazines; Societies, Medical; Thalidomide; Treatment Failure; Treatment Outcome | 2013 |
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Pyrazines; Thalidomide; Treatment Outcome | 2014 |
CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; B-Lymphocytes; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Ikaros Transcription Factor; Interferon Regulatory Factor-7; Interferons; Lenalidomide; Lentivirus; Lymphoma, Large B-Cell, Diffuse; Mice; Mice, SCID; Molecular Mimicry; Peptide Hydrolases; Piperidones; Proteolysis; Quinazolinones; RNA, Small Interfering; Signal Transduction; T-Lymphocytes; Thalidomide; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2015 |
Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Quality of Life; Thalidomide | 2015 |
Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myeloma.
Topics: Female; Humans; Immunity, Cellular; Interferon-gamma; Killer Cells, Natural; Lenalidomide; Male; Mucosal-Associated Invariant T Cells; Multiple Myeloma; Neoplasm Proteins; Thalidomide; Tumor Necrosis Factor Receptor Superfamily, Member 7 | 2018 |
Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cohort Studies; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Retrospective Studies; Thalidomide; Treatment Outcome | 2019 |
Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Survival Rate; Thalidomide | 2020 |
Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Resistance, Neoplasm; Febrile Neutropenia; Female; Frail Elderly; Frailty; Hematologic Diseases; Humans; Incidence; Infections; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prednisone; Progression-Free Survival; Recurrence; Republic of Korea; Thalidomide | 2020 |
OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Phenylalanine; Progression-Free Survival; Randomized Controlled Trials as Topic; Recurrence; Thalidomide | 2020 |
MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial.
Topics: ADP-ribosyl Cyclase 1; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide; Treatment Outcome | 2020 |
Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents.
Topics: Aged; Comorbidity; Consolidation Chemotherapy; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Immunologic Factors; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Myocardial Infarction; Pilot Projects; Proof of Concept Study; Prospective Studies; Pulmonary Embolism; Pyrazoles; Pyridones; Stroke; Thalidomide; Thrombophilia; Venous Thromboembolism; Venous Thrombosis | 2020 |
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Progression-Free Survival; Thalidomide | 2020 |
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Survival Rate; Thalidomide | 2021 |
B-cell maturation antigen chimeric antigen receptor T-cell re-expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitor-based combination therapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B-Cell Maturation Antigen; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Female; Humans; Immune Checkpoint Inhibitors; Immunotherapy, Adoptive; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Programmed Cell Death 1 Receptor; Receptors, Chimeric Antigen; Survival Rate; Thalidomide | 2021 |
3-weekly daratumumab-lenalidomide/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Survival Rate; Thalidomide | 2021 |
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Recurrence; Retreatment; Thalidomide; Treatment Outcome | 2022 |
A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Drug Resistance, Neoplasm; Female; Glycine; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Proteasome Inhibitors; Thalidomide | 2021 |
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; COVID-19 Drug Treatment; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Phenylalanine; SARS-CoV-2; Thalidomide | 2022 |
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Disease-Free Survival; Female; Glycine; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Progression-Free Survival; Proteasome Inhibitors; Thalidomide | 2022 |
Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasms, Plasma Cell; Quality of Life; Thalidomide | 2022 |
Exposure-response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide | 2022 |
Bendamustine in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: A phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2022 |
Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Leukopenia; Multiple Myeloma; Prospective Studies; Thalidomide | 2022 |
Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Survival Analysis | 2023 |
Multi-omic analysis of the tumor microenvironment shows clinical correlations in Ph1 study of atezolizumab +/- SoC in MM.
Topics: Humans; Lenalidomide; Multiomics; Multiple Myeloma; Proteomics; Tumor Microenvironment | 2023 |
Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pneumonia | 2023 |
117 other study(ies) available for lenalidomide and pomalidomide
| Article | Year |
|---|---|
Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production.
Topics: Blood; Humans; Inhibitory Concentration 50; Models, Chemical; Structure-Activity Relationship; Thalidomide; Tumor Necrosis Factor-alpha; U937 Cells | 1999 |
Angiogenesis inhibitors derived from thalidomide.
Topics: Angiogenesis Inhibitors; Endothelium, Vascular; Humans; Structure-Activity Relationship; Thalidomide; Umbilical Veins | 2005 |
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide.
Topics: Adaptor Proteins, Signal Transducing; Adjuvants, Immunologic; Antineoplastic Agents; HEK293 Cells; Humans; Lenalidomide; Peptide Hydrolases; Thalidomide; Ubiquitin-Protein Ligases; Ubiquitination | 2012 |
Isosteric analogs of lenalidomide and pomalidomide: synthesis and biological activity.
Topics: Administration, Oral; Animals; Cell Line, Tumor; Cell Proliferation; Half-Life; Humans; Interleukin-2; Lenalidomide; Leukocytes, Mononuclear; Rats; Structure-Activity Relationship; T-Lymphocytes; Thalidomide; Tumor Necrosis Factor-alpha | 2013 |
Protein Degradation via CRL4
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Chemistry Techniques, Synthetic; Drug Evaluation, Preclinical; Humans; Ikaros Transcription Factor; Molecular Docking Simulation; Multiple Myeloma; Peptide Hydrolases; Peptide Termination Factors; Phthalimides; Piperidones; Proteolysis; Quantitative Structure-Activity Relationship; Ubiquitin-Protein Ligases | 2018 |
A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos.
Topics: Adaptor Proteins, Signal Transducing; Cell Line, Tumor; Crystallography, X-Ray; DNA-Binding Proteins; Fluorescence Resonance Energy Transfer; Heterocyclic Compounds, 4 or More Rings; Humans; Ikaros Transcription Factor; Lenalidomide; Morpholines; Multiple Myeloma; Peptide Hydrolases; Phthalimides; Piperidones; Protein Binding; Proteolysis; Ubiquitin-Protein Ligases | 2018 |
From Inhibition to Degradation: Targeting the Antiapoptotic Protein Myeloid Cell Leukemia 1 (MCL1).
Topics: Cell Line; Humans; Indoles; Models, Molecular; Myeloid Cell Leukemia Sequence 1 Protein; Proteasome Endopeptidase Complex; Protein Conformation; Proteolysis; Sulfonamides; Ubiquitination | 2019 |
De-Novo Design of Cereblon (CRBN) Effectors Guided by Natural Hydrolysis Products of Thalidomide Derivatives.
Topics: Adaptor Proteins, Signal Transducing; Cell Line; Drug Design; Humans; Hydrolysis; Ikaros Transcription Factor; Molecular Docking Simulation; Proteolysis; Thalidomide; Ubiquitin-Protein Ligases | 2019 |
Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Female; Humans; Inhibitory Concentration 50; Mice; Multiple Myeloma; Recurrence; Stereoisomerism; Treatment Failure; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2020 |
Induced protein degradation of histone deacetylases 3 (HDAC3) by proteolysis targeting chimera (PROTAC).
Topics: A549 Cells; Adaptor Proteins, Signal Transducing; Anilides; Animals; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Mice; Phenylenediamines; Proteolysis; RAW 264.7 Cells; Thalidomide; Ubiquitin-Protein Ligases | 2020 |
Antimyeloma Potential of Caffeic Acid Phenethyl Ester and Its Analogues through Sp1 Mediated Downregulation of IKZF1-IRF4-MYC Axis.
Topics: Angiogenesis Inhibitors; Apoptosis; Caffeic Acids; Cell Line, Tumor; Down-Regulation; Genes, myc; Humans; Ikaros Transcription Factor; Interferon Regulatory Factors; Lenalidomide; Multiple Myeloma; Phenylethyl Alcohol; Sp1 Transcription Factor; Structure-Activity Relationship | 2020 |
Sweet and Blind Spots in E3 Ligase Ligand Space Revealed by a Thermophoresis-Based Assay.
Topics: | 2021 |
In pursuit of a selective hepatocellular carcinoma therapeutic agent: Novel thalidomide derivatives with antiproliferative, antimigratory and STAT3 inhibitory properties.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Liver Neoplasms; Molecular Structure; STAT3 Transcription Factor; Structure-Activity Relationship; Sulfides; Tumor Cells, Cultured | 2021 |
Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation.
Topics: Animals; Cell Proliferation; Dasatinib; Drug Design; Fusion Proteins, bcr-abl; Half-Life; Humans; K562 Cells; Lenalidomide; Ligands; Mice; Neoplasms; Protein Kinase Inhibitors; Proteolysis; Structure-Activity Relationship; Thalidomide; Transplantation, Heterologous; Ubiquitin-Protein Ligases | 2021 |
Physicochemistry of Cereblon Modulating Drugs Determines Pharmacokinetics and Disposition.
Topics: | 2021 |
Structure-based rational design enables efficient discovery of a new selective and potent AKT PROTAC degrader.
Topics: Cell Line, Tumor; Drug Design; Humans; Neoplasms; Proteolysis; Proto-Oncogene Proteins c-akt | 2022 |
Immunomodulatory analogs of thalidomide: an emerging new therapy in myeloma.
Topics: Clinical Trials as Topic; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Thalidomide | 2004 |
Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-alpha, IL-1beta, and LPS-stimulated human PBMC in a partially IL-10-dependent manner.
Topics: Blotting, Northern; Blotting, Western; Cyclooxygenase 2; Dinoprostone; Enzyme-Linked Immunosorbent Assay; Humans; Immunologic Factors; Interleukin-10; Isoenzymes; Lenalidomide; Leukocytes, Mononuclear; Lipopolysaccharides; Lymphocyte Activation; Lymphotoxin-alpha; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; RNA; Thalidomide; Tumor Necrosis Factor-alpha | 2004 |
Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Apoptosis; Cell Line, Tumor; Cell Proliferation; DNA; Drug Therapy, Combination; Female; Flow Cytometry; Humans; Immunologic Factors; Killer Cells, Natural; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Mice; Mice, SCID; Rituximab; Survival Analysis; Thalidomide; Treatment Outcome; Xenograft Model Antitumor Assays | 2005 |
Novel agents for multiple myeloma treatment.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Delivery Systems; Drug Design; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2006 |
Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells.
Topics: Antigens, CD34; Antineoplastic Agents; B-Lymphocytes; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Hematopoietic Stem Cells; Humans; Lenalidomide; Lymphoma, B-Cell; Phosphorylation; Retinoblastoma Protein; Thalidomide; Up-Regulation | 2007 |
Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Cytotoxicity, Immunologic; Dendritic Cells; Drug Interactions; Immunohistochemistry; Immunosuppressive Agents; Killer Cells, Natural; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mice, SCID; Microcirculation; Neovascularization, Pathologic; Rituximab; Thalidomide | 2008 |
Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells.
Topics: Anemia, Sickle Cell; Antigens, CD34; Antineoplastic Agents; Antisickling Agents; beta-Thalassemia; Blood Transfusion; Cells, Cultured; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Synergism; Erythroid Cells; Erythropoiesis; Fetal Hemoglobin; Humans; Hydroxyurea; Lenalidomide; Models, Biological; Thalidomide; Up-Regulation | 2008 |
Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Coculture Techniques; Drug Screening Assays, Antitumor; Flow Cytometry; Humans; Killer Cells, Natural; Lenalidomide; Leukocytes, Mononuclear; Lymphoma, Non-Hodgkin; Male; Neoplasms; Prostatic Neoplasms; Thalidomide | 2008 |
Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation.
Topics: Alkaline Phosphatase; Apoptosis; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Boronic Acids; Bortezomib; Cell Differentiation; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Osteoblasts; Osteoclasts; Pyrazines; Thalidomide; Transforming Growth Factor beta | 2008 |
The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions.
Topics: Adherens Junctions; Angiogenesis Inhibitors; Animals; Antigens, CD; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; beta Catenin; Cadherins; Cell Differentiation; Cell Hypoxia; Cell Line, Tumor; Cells, Cultured; Endothelial Cells; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; In Vitro Techniques; Lenalidomide; Lung Neoplasms; Melanoma, Experimental; Mice; Microcirculation; Neoplasm Metastasis; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Pregnancy; Proto-Oncogene Proteins c-akt; Thalidomide; Umbilical Arteries | 2009 |
The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Female; Forkhead Transcription Factors; Glucocorticoid-Induced TNFR-Related Protein; Humans; Immunosuppressive Agents; Interleukin-10; Lenalidomide; Mice; Mice, Inbred BALB C; Receptors, Nerve Growth Factor; Receptors, OX40; Receptors, Transforming Growth Factor beta; Receptors, Tumor Necrosis Factor; T-Lymphocytes, Regulatory; Thalidomide; Transforming Growth Factor beta | 2009 |
A microarray study of altered gene expression in colorectal cancer cells after treatment with immunomodulatory drugs: differences in action in vivo and in vitro.
Topics: Animals; Biomarkers; Blotting, Western; Cell Line, Tumor; Cluster Analysis; Colorectal Neoplasms; Female; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Immunologic Factors; Lenalidomide; Lymphocytes; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Oligonucleotide Array Sequence Analysis; Quality Control; Reproducibility of Results; Reverse Transcriptase Polymerase Chain Reaction; Thalidomide | 2010 |
Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs).
Topics: Animals; Antineoplastic Agents; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Immunoblotting; Immunohistochemistry; Immunologic Factors; Lenalidomide; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasm Invasiveness; Neoplasm Metastasis; Signal Transduction; Thalidomide; Tumor Cells, Cultured | 2009 |
Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism.
Topics: Antineoplastic Agents; Cell Line, Tumor; Chromatin; Cyclin-Dependent Kinase Inhibitor p21; Gene Expression Regulation, Neoplastic; Histone Demethylases; Histones; Humans; Lenalidomide; Lymphoma; Multiple Myeloma; Oxidoreductases, N-Demethylating; Thalidomide; Transcription Factors | 2009 |
Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia.
Topics: Antineoplastic Agents; Cell Differentiation; Cells, Cultured; Down-Regulation; Granulocyte Colony-Stimulating Factor; Granulocyte Precursor Cells; Granulocytes; Humans; Immunologic Factors; Lenalidomide; Models, Biological; Multiple Myeloma; Myeloid Progenitor Cells; Neutropenia; Neutrophils; Platelet Aggregation; Proto-Oncogene Proteins; Risk Factors; Thalidomide; Trans-Activators; Venous Thromboembolism | 2010 |
Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma.
Topics: Antineoplastic Agents; Bone Marrow Cells; Cell Line, Tumor; Cytokines; Epigenesis, Genetic; Humans; Immunologic Factors; Killer Cells, Natural; Lenalidomide; Multiple Myeloma; Signal Transduction; Stromal Cells; Suppressor of Cytokine Signaling 1 Protein; Suppressor of Cytokine Signaling Proteins; T-Lymphocytes; Thalidomide | 2010 |
Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs.
Topics: Amyloid; Amyloidosis; Biomarkers; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Drug Therapy, Combination; Heart Failure; Humans; Immunoglobulin Light Chains; Immunologic Factors; Lenalidomide; Melphalan; Natriuretic Peptide, Brain; Patient Dropouts; Peptide Fragments; Stem Cell Transplantation; Thalidomide; Troponin T | 2010 |
Recent advances in myeloma treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Medical Oncology; Melphalan; Multiple Myeloma; Oligopeptides; Prednisone; Pyrazines; Quality of Life; Salvage Therapy; Stem Cell Transplantation; Thalidomide | 2011 |
IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM.
Topics: Apoptosis; Blotting, Western; CCAAT-Enhancer-Binding Protein-beta; Cell Separation; Down-Regulation; Eukaryotic Initiation Factor-4E; Flow Cytometry; Gene Expression Regulation; Gene Knockdown Techniques; Humans; Immunohistochemistry; Immunologic Factors; Interferon Regulatory Factors; Lenalidomide; Multiple Myeloma; Protein Biosynthesis; Reverse Transcriptase Polymerase Chain Reaction; Thalidomide; Transfection | 2011 |
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Biomarkers, Pharmacological; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Line, Tumor; Chromosome Aberrations; Comparative Genomic Hybridization; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Immunologic Factors; Lenalidomide; Models, Biological; Multiple Myeloma; Peptide Hydrolases; Pyrazines; RNA, Small Interfering; Thalidomide; Ubiquitin-Protein Ligases | 2011 |
A third-generation IMiD for MM.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Pyrazines; Thalidomide | 2011 |
Expansion of polyfunctional HIV-specific T cells upon stimulation with mRNA electroporated dendritic cells in the presence of immunomodulatory drugs.
Topics: CD8-Positive T-Lymphocytes; Cells, Cultured; Dendritic Cells; Electroporation; gag Gene Products, Human Immunodeficiency Virus; HIV Infections; HIV-1; Humans; Immunologic Factors; Lenalidomide; nef Gene Products, Human Immunodeficiency Virus; RNA, Messenger; Species Specificity; Thalidomide | 2012 |
Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules.
Topics: Antineoplastic Agents; Cell Adhesion Molecules; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Chemokine CCL3; Coculture Techniques; Dose-Response Relationship, Drug; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunologic Factors; Integrin alpha4; Lenalidomide; Multiple Myeloma; Osteoblasts; Osteoprotegerin; RANK Ligand; Reverse Transcriptase Polymerase Chain Reaction; Thalidomide; Tumor Cells, Cultured; Tumor Microenvironment | 2013 |
Enhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs® immunomodulatory compounds lenalidomide and pomalidomide.
Topics: Animals; Antigen Presentation; Antigens, Neoplasm; CD8-Positive T-Lymphocytes; Cells, Cultured; Cross-Priming; Dendritic Cells; Female; Immunologic Factors; Lenalidomide; Lymphocyte Activation; Mice; Mice, Inbred C57BL; Ovalbumin; Thalidomide | 2013 |
"IM iD"eally treating multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Pyrazines; Thalidomide | 2013 |
The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Drug Tolerance; Female; Humans; Lenalidomide; Logistic Models; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Oligopeptides; Outcome Assessment, Health Care; Prognosis; Pyrazines; Retrospective Studies; Risk Factors; Survival Analysis; Thalidomide | 2014 |
Pomalidomide in the treatment of relapsed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide | 2013 |
Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro.
Topics: Angiogenesis Inhibitors; Animals; Chick Embryo; Chickens; Lenalidomide; Neovascularization, Physiologic; Neurites; Neurotoxins; Species Specificity; Teratogens; Thalidomide; Zebrafish | 2013 |
[II. Immunomodulation for multiple myeloma].
Topics: Bone Marrow Transplantation; Glucosides; Humans; Immunomodulation; Lenalidomide; Multiple Myeloma; Phenols; Thalidomide | 2013 |
Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy.
Topics: Adaptor Proteins, Signal Transducing; Adjuvants, Immunologic; DNA-Binding Proteins; Humans; Lenalidomide; Mutation; Peptide Hydrolases; Thalidomide; Ubiquitin-Protein Ligases | 2014 |
Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).
Topics: Adaptor Proteins, Signal Transducing; Angiogenesis Inhibitors; Humans; Ikaros Transcription Factor; Immunologic Factors; Lenalidomide; Peptide Hydrolases; Proteasome Endopeptidase Complex; T-Lymphocytes; Thalidomide; Transcription Factors; Transfection; Ubiquitin-Protein Ligases; Ubiquitination | 2014 |
An overview of the progress in the treatment of multiple myeloma.
Topics: Angiogenesis Inhibitors; Drug Therapy, Combination; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Stem Cell Transplantation; Thalidomide | 2014 |
Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.
Topics: Adaptor Proteins, Signal Transducing; alpha Karyopherins; Anti-Inflammatory Agents; Biomarkers, Tumor; Blotting, Western; Carrier Proteins; Clinical Trials, Phase II as Topic; Dexamethasone; Drug Resistance, Neoplasm; Flow Cytometry; Follow-Up Studies; Humans; Ikaros Transcription Factor; Immunologic Factors; Immunoprecipitation; Lenalidomide; Multiple Myeloma; Peptide Hydrolases; Prognosis; Prospective Studies; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Survival Rate; Thalidomide; Tumor Cells, Cultured; Ubiquitin-Protein Ligases | 2014 |
Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Dendritic Cells; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Immunomodulation; Immunotherapy, Adoptive; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Vincristine | 2014 |
Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide.
Topics: Adaptor Proteins, Signal Transducing; Crystallography, X-Ray; DNA-Binding Proteins; Homeodomain Proteins; Humans; Lenalidomide; Models, Molecular; Multiprotein Complexes; Peptide Hydrolases; Protein Binding; Structure-Activity Relationship; Substrate Specificity; Thalidomide; Transcription Factors; Ubiquitin-Protein Ligases | 2014 |
In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Apoptosis; Benzimidazoles; Cell Line, Tumor; Dexamethasone; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Therapy, Combination; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Humans; Ikaros Transcription Factor; Lenalidomide; Mice; Multiple Myeloma; Neoplasm Transplantation; Nerve Tissue Proteins; Plasmacytoma; Signal Transduction; Thalidomide; Trans-Activators | 2015 |
NICE guidance on pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib.
Topics: Boronic Acids; Bortezomib; Disease-Free Survival; Drug Approval; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2015 |
Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Synergism; Flow Cytometry; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunoblotting; Immunomodulation; In Vitro Techniques; Lenalidomide; Multiple Myeloma; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Thalidomide; Transfection; Vorinostat | 2015 |
Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Azepines; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Gene Knockdown Techniques; Humans; Ikaros Transcription Factor; Immunologic Factors; Interferon Regulatory Factors; Lenalidomide; Lymphoma, Primary Effusion; Mice; Nuclear Proteins; Peptide Hydrolases; Proto-Oncogene Proteins c-myc; Thalidomide; Transcription Factors; Triazoles; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2016 |
A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function.
Topics: Adaptor Proteins, Signal Transducing; Cell Line, Tumor; HEK293 Cells; Humans; Lenalidomide; Multiple Myeloma; Peptide Hydrolases; Thalidomide; Ubiquitin-Protein Ligases; Ubiquitination | 2015 |
How I treat high-risk myeloma.
Topics: Aged; Antineoplastic Agents; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Thalidomide | 2015 |
Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Flow Cytometry; Gene Knockdown Techniques; Humans; Ikaros Transcription Factor; Immunoblotting; Immunohistochemistry; Interferon Regulatory Factors; Lenalidomide; Multiple Myeloma; Proto-Oncogene Proteins c-myc; RNA, Small Interfering; Signal Transduction; Thalidomide | 2015 |
Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Comorbidity; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Thalidomide | 2016 |
A retrospective study of direct cost to patients associated with the use of oral oncology medications for the treatment of multiple myeloma.
Topics: Angiogenesis Inhibitors; Community Pharmacy Services; Fees, Pharmaceutical; Female; Humans; Lenalidomide; Male; Medication Adherence; Multiple Myeloma; Retrospective Studies; Thalidomide | 2016 |
Immunomodulatory drugs inhibit TLR4-induced type-1 interferon production independently of Cereblon via suppression of the TRIF/IRF3 pathway.
Topics: Adaptor Proteins, Signal Transducing; Adaptor Proteins, Vesicular Transport; Animals; Cells, Cultured; Clustered Regularly Interspaced Short Palindromic Repeats; Immunologic Factors; Immunosuppression Therapy; Inflammation; Interferon Regulatory Factor-3; Interferon Type I; Lenalidomide; Macrophages; Mice; Mice, Inbred C57BL; Mice, Knockout; Nerve Tissue Proteins; Signal Transduction; Thalidomide; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha | 2016 |
Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Dexamethasone; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Immunomodulation; Lenalidomide; Mice, SCID; Multiple Myeloma; Thalidomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Austria; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Prognosis; Recurrence; Registries; Retrospective Studies; Survival Analysis; Thalidomide; Transplantation, Autologous | 2016 |
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chromosome Aberrations; Combined Modality Therapy; Consensus; Cytogenetics; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Risk Factors; Thalidomide; Transplantation, Autologous | 2016 |
Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cost-Benefit Analysis; Dexamethasone; Health Care Costs; Humans; Lenalidomide; Life Expectancy; Male; Middle Aged; Models, Economic; Multiple Myeloma; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recurrence; Sweden; Thalidomide; Treatment Outcome | 2016 |
Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity.
Topics: Adaptor Proteins, Signal Transducing; Basigin; Cell Cycle Proteins; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Oncogene Proteins; Peptide Hydrolases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Teratogenesis; Thalidomide; Ubiquitin-Protein Ligases | 2016 |
Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein-Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression.
Topics: Animals; Cell Line, Tumor; Epstein-Barr Virus Infections; Herpesvirus 4, Human; Humans; Ikaros Transcription Factor; Immunologic Factors; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; Neoplasms, Second Primary; Phosphatidylinositol 3-Kinases; Thalidomide; Virus Activation; Virus Latency | 2016 |
Expansion of Th
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Diphosphonates; Humans; Imidazoles; Immunologic Factors; Lenalidomide; Multiple Myeloma; T-Lymphocytes; Th1 Cells; Thalidomide; Zoledronic Acid | 2017 |
Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Collagen Type II; Dextran Sulfate; Disease Models, Animal; Immunologic Factors; Inflammatory Bowel Diseases; Lenalidomide; Male; Mice; Mice, Inbred C57BL; Thalidomide; Trinitrobenzenesulfonic Acid | 2017 |
Diagnosis and treatment of multiple myeloma in Germany: analysis of a nationwide multi-institutional survey.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus; Female; Germany; Health Surveys; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide; Transplantation, Autologous | 2017 |
Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner.
Topics: Adaptor Proteins, Signal Transducing; Azacitidine; Benzamides; Biphenyl Compounds; Cell Line, Tumor; Chromatin; DNA Methylation; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Gene Expression; Gene Expression Profiling; Humans; Lenalidomide; Morpholines; Multiple Myeloma; Peptide Hydrolases; Pyridones; Thalidomide; Ubiquitin-Protein Ligases | 2018 |
The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2018 |
Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Myeloma Proteins; Survival Rate; Thalidomide; Treatment Outcome | 2018 |
Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease Progression; Female; France; Health Expenditures; Health Resources; Hospitalization; Humans; Italy; Lenalidomide; Male; Middle Aged; Models, Econometric; Multiple Myeloma; Retrospective Studies; Thalidomide; United Kingdom | 2018 |
The struggle to do no harm in clinical trials.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD19; Child; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Immunotherapy; Inflammation; Lenalidomide; Male; Neoplasms; Nivolumab; Prognosis; Programmed Cell Death 1 Receptor; Risk Management; T-Lymphocytes; Thalidomide; Treatment Outcome; Vidarabine | 2017 |
Evaluating the use of appropriate anticoagulation with lenalidomide and pomalidomide in patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pulmonary Embolism; Retrospective Studies; Thalidomide; Venous Thromboembolism | 2019 |
Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Agents; CD56 Antigen; Cells, Cultured; Cytotoxicity, Immunologic; Genes, MHC Class I; Humans; Immunologic Factors; K562 Cells; Killer Cells, Natural; Lenalidomide; Leukemia, Myeloid, Acute; Male; Mice; Middle Aged; Monitoring, Immunologic; Natural Cytotoxicity Triggering Receptor 3; Thalidomide; Xenograft Model Antitumor Assays | 2018 |
Efficient Synthesis of Immunomodulatory Drug Analogues Enables Exploration of Structure-Degradation Relationships.
Topics: Adaptor Proteins, Signal Transducing; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Peptide Hydrolases; Structure-Activity Relationship; Thalidomide; Ubiquitin-Protein Ligases | 2018 |
CK1α and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma.
Topics: Casein Kinase Ialpha; Cell Line, Tumor; CRISPR-Cas Systems; Down-Regulation; Gene Expression Regulation, Neoplastic; Gene Knockout Techniques; Humans; Ikaros Transcription Factor; Immunologic Factors; Interferon Regulatory Factors; Lenalidomide; Lymphoma, Primary Effusion; Molecular Targeted Therapy; Neoplasm Proteins; RNA Interference; RNA, Small Interfering; Signal Transduction; Thalidomide; Ubiquitin-Protein Ligases | 2018 |
Successful retreatment with lenalidomide for relapsed and refractory multiple myeloma previously treated with bortezomib, lenalidomide and pomalidomide.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Lenalidomide; Male; Multiple Myeloma; Recurrence; Retreatment; Thalidomide; Treatment Outcome | 2018 |
Multiple myeloma: Updated approach to management in 2018.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; beta 2-Microglobulin; Bortezomib; Disease Management; Humans; Hypercalcemia; Immunologic Factors; Lenalidomide; Multiple Myeloma; Oligopeptides; Pain; Prognosis; Renal Insufficiency; Serum Albumin; Thalidomide | 2018 |
Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN.
Topics: Adaptor Proteins, Signal Transducing; Amino Acid Sequence; CYS2-HIS2 Zinc Fingers; HEK293 Cells; Humans; Ikaros Transcription Factor; Lenalidomide; Peptide Hydrolases; Proteolysis; Proteome; Thalidomide; Ubiquitin-Protein Ligases; Ubiquitination | 2018 |
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Drug Evaluation; Drug Substitution; Female; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Progression-Free Survival; Protease Inhibitors; Recurrence; Retrospective Studies; Salvage Therapy; Thalidomide | 2019 |
Multiple myeloma immunoglobulin lambda translocations portend poor prognosis.
Topics: Antineoplastic Agents; DNA Copy Number Variations; Drug Resistance, Neoplasm; Enhancer Elements, Genetic; Gene Expression Regulation, Neoplastic; Genetic Loci; Genome, Human; Humans; Ikaros Transcription Factor; Immunoglobulin lambda-Chains; Immunologic Factors; Lenalidomide; Multiple Myeloma; Myeloma Proteins; Plasma Cells; Prognosis; Protein Binding; Proto-Oncogene Proteins c-myc; Recurrence; Survival Analysis; Thalidomide; Translocation, Genetic; Whole Genome Sequencing | 2019 |
Redefining the treatment paradigm for multiple myeloma.
Topics: Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2019 |
HDAC6‑selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in multiple myeloma.
Topics: Apoptosis; Benzene Derivatives; Cell Proliferation; Drug Synergism; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Thalidomide; Tumor Cells, Cultured | 2019 |
Facing lenalidomide-refractory myeloma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2019 |
Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Humans; Lenalidomide; Mice; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; Signaling Lymphocytic Activation Molecule Family; Thalidomide; Xenograft Model Antitumor Assays | 2020 |
Pomalidomide in lenalidomide-refractory multiple myeloma: Far from futile.
Topics: Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Treatment Failure | 2020 |
Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Resistance, Neoplasm; Heterocyclic Compounds, 4 or More Rings; Humans; Lenalidomide; Leukocytes, Mononuclear; Morpholines; Multiple Myeloma; Phthalimides; Piperidones; Thalidomide; Tumor Cells, Cultured; Ubiquitin-Protein Ligases | 2020 |
Discovery of a new class of PROTAC BRD4 degraders based on a dihydroquinazolinone derivative and lenalidomide/pomalidomide.
Topics: Cell Cycle Proteins; Cell Line; Cell Proliferation; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Discovery; HL-60 Cells; Humans; Lenalidomide; Models, Molecular; Molecular Structure; Quinazolinones; Structure-Activity Relationship; Thalidomide; THP-1 Cells; Transcription Factors | 2020 |
Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Dosage Calculations; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Progression-Free Survival; Thalidomide | 2019 |
Pyoderma gangrenosum induced by lenalidomide in a case of multiple myeloma.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Substitution; Febrile Neutropenia; Granulocyte Colony-Stimulating Factor; Humans; Immunologic Factors; Lenalidomide; Male; Multiple Myeloma; Piperacillin, Tazobactam Drug Combination; Pyoderma Gangrenosum; Thalidomide | 2020 |
Immunomodulatory Drugs Alter the Metabolism and the Extracellular Release of Soluble Mediators by Normal Monocytes.
Topics: Cell Respiration; Cytokines; Energy Metabolism; Glycolysis; Humans; Immunologic Factors; Lenalidomide; Lipopolysaccharides; Monocytes; Oxidative Phosphorylation; Thalidomide; Toll-Like Receptor 4 | 2020 |
A Cell-Based Target Engagement Assay for the Identification of Cereblon E3 Ubiquitin Ligase Ligands and Their Application in HDAC6 Degraders.
Topics: Adaptor Proteins, Signal Transducing; Cell Line; Histone Deacetylase 6; Humans; Lenalidomide; Ligands; Protein Binding; Proteolysis; Thalidomide; Ubiquitin-Protein Ligases | 2020 |
A452, HDAC6-selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in IMiDs-resistant multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzene Derivatives; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Thalidomide | 2020 |
Lenalidomide and pomalidomide potently interfere with induction of myeloid-derived suppressor cells in multiple myeloma.
Topics: Cell Line, Tumor; Chemokine CCL5; Coculture Techniques; Humans; Interferon Regulatory Factors; Intramolecular Oxidoreductases; Lenalidomide; Macrophage Migration-Inhibitory Factors; Multiple Myeloma; Myeloid-Derived Suppressor Cells; Neoplasm Proteins; Thalidomide | 2020 |
Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers.
Topics: Academic Medical Centers; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Thalidomide | 2021 |
The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models.
Topics: Animals; Humans; Immunomodulation; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; Pharmaceutical Preparations; Thalidomide | 2020 |
Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; CD8-Positive T-Lymphocytes; Cell Proliferation; Dexamethasone; Female; Humans; Immunomodulation; Immunophenotyping; Killer Cells, Natural; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; T-Lymphocytes, Regulatory; Thalidomide | 2020 |
ARID2 is a pomalidomide-dependent CRL4
Topics: Antineoplastic Agents; Cell Line, Tumor; Chromosomal Proteins, Non-Histone; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression Regulation; Gene Knockdown Techniques; Humans; Lenalidomide; Multiple Myeloma; Mutation; Protein Binding; Proteolysis; RNA, Messenger; RNA, Small Interfering; Thalidomide; Time Factors; Transcription Factors; Ubiquitin-Protein Ligases; Ubiquitination | 2020 |
Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn
Topics: Adaptor Proteins, Signal Transducing; Animals; Cell Line, Tumor; Cell Survival; Female; HEK293 Cells; Humans; Immunologic Factors; Lenalidomide; Mice; Mice, Inbred BALB C; Multiple Myeloma; Point Mutation; Proteolysis; Thalidomide; Ubiquitin-Protein Ligases | 2021 |
Frequent occurrence of hypophosphatemia among multiple myeloma patients treated with elotuzumab: a single clinic retrospective study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Diphosphonates; Drug Interactions; Female; Humans; Hypophosphatemia; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Retrospective Studies; Thalidomide | 2021 |
Design, synthesis and biological evaluation of thioether-containing lenalidomide and pomalidomide derivatives with anti-multiple myeloma activity.
Topics: Animals; Cell Proliferation; Drug Design; Female; Humans; Immunologic Factors; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; Sulfides; Thalidomide; Xenograft Model Antitumor Assays | 2021 |
Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Drug Resistance, Neoplasm; Genetic Variation; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Ubiquitin-Protein Ligases | 2021 |
Elotuzumab in the treatment of relapsed and refractory multiple myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Line, Tumor; Clinical Trials as Topic; Dexamethasone; Drug Resistance, Neoplasm; Humans; Killer Cells, Natural; Lenalidomide; Mesenchymal Stem Cells; Multiple Myeloma; Neoplasm Recurrence, Local; Progression-Free Survival; Thalidomide | 2021 |
Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Practice Patterns, Physicians'; Progression-Free Survival; Proteasome Inhibitors; Retrospective Studies; Thalidomide; United States | 2021 |
Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase II as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Myeloma Proteins; Oligopeptides; Progression-Free Survival; Thalidomide | 2021 |
Incidence of skin hyperpigmentation in Black patients receiving treatment with immunomodulatory drugs.
Topics: Black or African American; Humans; Hyperpigmentation; Immunologic Factors; Incidence; Lenalidomide; Multiple Myeloma; Organ Specificity; Retrospective Studies; Thalidomide | 2021 |
Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Canada; Dexamethasone; Female; Glycine; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Recurrence; Retrospective Studies; Salvage Therapy; Survival Analysis; Thalidomide; Transplantation, Autologous | 2021 |
Lenalidomide and pomalidomide inhibit growth of prostate stromal cells and human prostate smooth muscle contraction.
Topics: Apoptosis; Cell Line, Transformed; Humans; Lenalidomide; Male; Muscle Contraction; Muscle, Smooth; Prostate; Stromal Cells; Thalidomide | 2021 |
Involvement of EZH2 inhibition in lenalidomide and pomalidomide-mediated growth suppression in HTLV-1-infected cells.
Topics: Antiviral Agents; Cell Line; Cell Proliferation; Enhancer of Zeste Homolog 2 Protein; HTLV-I Infections; Human T-lymphotropic virus 1; Humans; Lenalidomide; Microbial Sensitivity Tests; Thalidomide | 2021 |
Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14).
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2022 |
Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1.
Topics: Drug Resistance, Neoplasm; Humans; Ikaros Transcription Factor; Immunologic Factors; Lenalidomide; Lymphoma, T-Cell; Multiple Myeloma; Thalidomide; Ubiquitin-Protein Ligases; Ubiquitination | 2022 |
Pomalidomide, dexamethasone, and daratumumab in Japanese patients with relapsed or refractory multiple myeloma after lenalidomide-based treatment.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Japan; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide; Treatment Outcome | 2022 |
Efficacy and Safety of Replacing Lenalidomide with Pomalidomide for Patients with Multiple Myeloma Refractory to a Lenalidomide-Containing Combination Regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2022 |
Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients-Real-World Data From Hungary.
Topics: Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Hungary; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Treatment Outcome | 2022 |